> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Mylan Recalls Contaminated Valsartan Products
- URL: https://www.fdaweb.com/mylan-recalls-contaminated-valsartan-products/
- Published: 2018-11-21T12:00:00.000Z
- Updated: 2026-09-15T00:46:11.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5142880

FDA says Mylan Pharmaceuticals has recalled 15 lots of valsartan-containing products due to the presence of N-Nitrosodiethylamine (NDEA). The agency [notice](https://www.fda.gov/Drugs/DrugSafety/ucm613916.htm?ref=fdaweb.com) says that not all Mylan valsartan-containing products distributed in the U.S. are being recalled. The company is only recalling lots that tested positive for NDEA above the acceptable level.

The notice says FDA continues to investigate and test all angiotensin II receptor blockers for the presence of NDEA and N-Nitrosodimethylamine and to take action when it finds the impurities at above acceptable levels.